-
Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials
•
Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US firm Marnac’s pirfenidone, in the form of an inhalable solution, has been approved for clinical trials in China. The drug is aimed at treating idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by diffuse…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National Medical Product Administration (NMPA) for two of its drug candidates, SHR-1654 and SHR-2001. These molecules are set for assessment as potential treatments for rheumatoid arthritis and systemic lupus erythematosus, respectively. SHR-1654: A Novel Treatment for…
-
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
•
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food and Drug Administration (FDA) for its LAE102 antibody. The drug is set to be assessed as a potential treatment for non-small cell lung cancer (NSCLC). This achievement marks LAE102 as Laekna’s first internally-discovered drug candidate…
-
Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement
•
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in the city are set to carry out a special tender that links diagnosis-related group (DRG) reforms with volume-based procurement (VBP) for medical consumables in the sports medicine, neurointervention, and electrophysiology fields. The participating hospitals include…
-
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
•
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first quarter of 2023, highlighting an 11% year-on-year (YOY) increase in global sales revenues in constant exchange rate terms, reaching DKK 5.044 billion (USD 731.2 million). This figure marks the highest quarterly revenue in the company’s…
-
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
•
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration (FDA) has cleared the company’s second Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The clearance is for a Phase I/II study in patients with active idiopathic…
-
MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin off its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange. This move has been confirmed by the bourse, and MicroPort expects…
-
Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy
•
US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the US subsidiary of China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO). This deal will result in the sale of Mustang’s development, manufacturing, and analytical testing facility in Worcester, Massachusetts…
